Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Degeorge

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Experimental Animals|September 11, 2004
Value in global standardization of outbred rats for regulatory pharmaceuticals studiesHerman van Cauteren, Michael Kammüller, Joseph DeGeorge
Acta Crystallographica. Section E, Structure Reports Online|May 2, 2013
Phenazin-5-ium hydrogen sulfate monohydrateJoseph Degeorge, Christopher P Landee, Mark M Turnbull
International Journal of Toxicology|April 9, 2002
Evaluation of the Tg.AC transgenic mouse assay for testing the human carcinogenic potential of pharmaceuticals--practical pointers, mechanistic clues, and new questionsFrank D Sistare, Karol L Thompson, Ronald Honchel, et al.
Toxicology and Applied Pharmacology|August 14, 2016
Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav1.2 over-expressing cellsArmando Lagrutta, Haoyu Zeng, John Imredy, et al.
Scientific Reports|March 23, 2017
Cardiac drug-drug interaction between HCV-NS5B pronucleotide inhibitors and amiodarone is determined by their specific diastereochemistryArmando Lagrutta, Christopher P Regan, Haoyu Zeng, et al.
Clinical Pharmacology and Therapeutics|December 30, 2017
An Industry Perspective on the 2017 EMA Guideline on First-in-Human and Early Clinical TrialsJoseph DeGeorge, Sarah Robertson, Lynne Butler, et al.
ILAR Journal|May 5, 2022
Fit for Purpose Assessment: A New Direction for IACUCsLewis B Kinter, David K Johnson, Robert H Weichbrod, et al.
Inorganic Chemistry|February 3, 2012
Importance of halogen···halogen contacts for the structural and magnetic properties of CuX2(pyrazine-N,N′-dioxide)(H2O)2 (X = Cl and Br)John A Schlueter, Hyunsoo Park, Gregory J Halder, et al.
Regulatory Toxicology and Pharmacology : RTP|January 18, 2006
A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicityLutz Müller, Robert J Mauthe, Christopher M Riley, et al.
Regulatory Toxicology and Pharmacology : RTP|August 1, 2014
Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trialsFiona Sewell, Kathryn Chapman, Paul Baldrick, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Experimental Animals|September 11, 2004
Value in global standardization of outbred rats for regulatory pharmaceuticals studiesHerman van Cauteren, Michael Kammüller, Joseph DeGeorge
Acta Crystallographica. Section E, Structure Reports Online|May 2, 2013
Phenazin-5-ium hydrogen sulfate monohydrateJoseph Degeorge, Christopher P Landee, Mark M Turnbull
International Journal of Toxicology|April 9, 2002
Evaluation of the Tg.AC transgenic mouse assay for testing the human carcinogenic potential of pharmaceuticals--practical pointers, mechanistic clues, and new questionsFrank D Sistare, Karol L Thompson, Ronald Honchel, et al.
Toxicology and Applied Pharmacology|August 14, 2016
Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav1.2 over-expressing cellsArmando Lagrutta, Haoyu Zeng, John Imredy, et al.
Scientific Reports|March 23, 2017
Cardiac drug-drug interaction between HCV-NS5B pronucleotide inhibitors and amiodarone is determined by their specific diastereochemistryArmando Lagrutta, Christopher P Regan, Haoyu Zeng, et al.
Clinical Pharmacology and Therapeutics|December 30, 2017
An Industry Perspective on the 2017 EMA Guideline on First-in-Human and Early Clinical TrialsJoseph DeGeorge, Sarah Robertson, Lynne Butler, et al.
ILAR Journal|May 5, 2022
Fit for Purpose Assessment: A New Direction for IACUCsLewis B Kinter, David K Johnson, Robert H Weichbrod, et al.
Inorganic Chemistry|February 3, 2012
Importance of halogen···halogen contacts for the structural and magnetic properties of CuX2(pyrazine-N,N′-dioxide)(H2O)2 (X = Cl and Br)John A Schlueter, Hyunsoo Park, Gregory J Halder, et al.
Regulatory Toxicology and Pharmacology : RTP|January 18, 2006
A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicityLutz Müller, Robert J Mauthe, Christopher M Riley, et al.
Regulatory Toxicology and Pharmacology : RTP|August 1, 2014
Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trialsFiona Sewell, Kathryn Chapman, Paul Baldrick, et al.
Pageof 1